Browse the corpus

Cholestatic jaundice results from impaired bile flow, accumulating bile components, such as bilirubin, in the bloodstream. This condition can be classified as intrahepatic, caused by issues within the liver, or extrahepatic, resulting from obstructions outside the liver. Common clinical manifestations include jaundice, pruritus, fatigue, malabsorption of fats and fat-soluble vitamins, and the appearance of skin lesions such as xanthomas. The condition has diverse etiologies, including viral hepatitis, medication-induced cholestasis, and bile duct obstructions like gallstones or tumors. Diagnosis typically involves a combination of clinical evaluation, liver function tests, imaging studies, and, in some cases, liver biopsy. Treatment approaches focus on addressing the underlying cause and alleviating symptoms, with options ranging from medical management to surgical intervention or liver transplantation in severe cases. The course equips participants with the knowledge and skills to effectively recognize and evaluate cholestatic jaundice. Emphasis is placed on interpreting diagnostic tests, identifying underlying causes, and implementing appropriate treatment plans. Participants gain insights into the value of interprofessional collaboration, learning how coordinated efforts among clinicians, nurses, radiologists, and dietitians contribute to improved patient outcomes. The course highlights how shared expertise from the interprofessional healthcare team ensures comprehensive care, enhances symptom management, and optimizes long-term health for individuals affected by this condition. Objectives: Differentiate between intrahepatic and extrahepatic causes of cholestasis based on patient history, laboratory findings, and imaging results. Screen at-risk populations for potential etiologies of cholestatic jaundice, such as viral hepatitis, medication use, or bile duct obstructions. Implement appropriate diagnostic protocols, including liver function tests, imaging studies, and, when necessary, liver biopsy. Apply interprofessional team strategies to improve care coordination and outcomes in patients with cholestatic jaundice. Access free multiple choice questions on this topic.

Cholestatic jaundice occurs due to cholestasis, a condition where bile flow significantly reduces or completely stops, leading to bile components (eg, bilirubin) accumulating in the bloodstream. Cholestasis can result from functional impairment of the hepatocytes in the secretion of bile or due to an obstruction at any level of the excretory pathway of bile, from the level of the hepatic parenchymal cells at the basolateral (sinusoidal) membrane of the hepatocyte to the ampulla of Vater in the duodenum. Cholestatic jaundice can be classified into intrahepatic or extrahepatic cholestasis, depending upon the level of obstruction to bile flow. Intrahepatic or functional cholestasis can be due to a condition involving the liver parenchymal cells or the intrahepatic bile ducts. Extrahepatic or obstructive cholestasis is due to an excretory block outside the liver and the extrahepatic bile ducts. Furthermore, intrahepatic cholestasis can be further subclassified as intralobular, affecting liver parenchymal cells and transporter molecules, or extralobular, affecting intrahepatic bile ducts.[1][2][3][4][5] Clinically, cholestasis leads to the retention of bile constituents in the blood. The 2 primary constituents of bile are bilirubin and bile acids. Histologically, the retention of bilirubin in the hepatocytes, bile canaliculi, or bile ducts causes bilirubinostasis, which clinically manifests as jaundice. Biochemically, cholestasis is marked by the elevation of predominantly serum alkaline phosphatase. On the other hand, the stagnation of bile acids causes typical changes in the periportal region of the liver, termed cholate stasis, and presents clinically as pruritus. As the excretion of bilirubin follows hepatocellular pathways different from those of bile acids, serum bilirubin level may be normal in some instances of severe cholestasis (eg, anicteric cholestasis), and the patient may present with pruritus without jaundice. Prominent features of cholestasis are pruritus and malabsorption of fat and fat-soluble vitamins.

Extrahepatic Cholestasis Extrahepatic or obstructive cholestasis is due to an excretory block outside the liver and the extrahepatic bile ducts secondary to conditions including: Choledocholithiasis Benign bile duct strictures Primary or secondary sclerosing cholangitis Mirizzi syndrome Cholangiocarcinoma Pancreatic cancer Ampullary adenoma/carcinoma [6] Intrahepatic Cholestasis Intrahepatic or functional cholestasis is typically caused by conditions involving the liver parenchymal cells or the intrahepatic bile ducts, including: Hepatocellular causes Viral hepatitis Acute alcohol-related hepatitis Parenteral nutrition Intrahepatic atresia (infantile cholangiopathy) Zellweger syndrome Canalicular membrane changes Medication (eg, contraceptive pills, antibiotics, antithyroid drugs, sulfonamides) [7] Cholestasis of pregnancy Genetic defects in bile transporters Benign recurrent intrahepatic cholestasis Progressive familial intrahepatic cholestasis Canalicular and ductular luminal obstruction Cholestasis due to sickle cell disease Hereditary protoporphyria Bacterial infections, sepsis Cystic fibrosis Ductopenia Familial, drug-induced, chronic allograft rejection, Hodgkin disease, sarcoidosis, primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC) [6]

Cholestasis can be observed in all age groups. However, due to the immaturity of the liver, the pediatric and adolescent age groups are more susceptible to cholestasis. No significant difference in the prevalence of cholestatic jaundice between males and females has been reported.[4] However, females are at a slightly higher risk of biliary atresia, drug-induced cholestasis, and intrahepatic cholestasis during pregnancy.

Cholestasis can occur in a hepatocellular pattern involving the complex bile synthesis and flow mechanism. Bile is a highly complex, water-soluble medium. Bile formation includes multiple different mechanisms of conjugation with multilevel regulation. The content of bile is transported in canaliculi via transport proteins, creating a chemical and osmotic gradient through which water enters the canaliculi. Identifying abnormalities within some of these transporter proteins has led to an improved understanding of the mechanism of certain diseases, including benign recurrent intrahepatic cholestasis (F1C1 locus gene) and progressive familial intrahepatic cholestasis (F1C2 locus gene). Failure to transport bile salts leads to its accumulation within the liver. The strong detergent-like effect of the bile salts causes membrane injury and impairment of membrane function. Another mechanism of cholestasis is the physical obstruction to bile flow at the level of extrahepatic biliary ducts; retained bile similarly causes hepatotoxicity.

The histologic findings of cholestatic jaundice are disease-specific. In patients with cholestasis secondary to hepatocellular causes, histology shows bile within hepatocytes and canaliculi spaces along with a diffuse cholestatic injury pattern. In cases due to obstructive cholestasis, histologic characteristics of bile plugging interlobular bile ducts, portal expansion, and bile duct proliferation are typically observed, with mainly a centrilobular pattern of cholestatic injury. Retention of bilirubin (ie, bilirubinostasis) can lead to stagnation of bile and bilirubin along cytoplasmic, canalicular, ductular, or ductal regions, depending on the severity and duration of biliary obstruction. Cholate stasis corresponds to the changes in the periportal hepatocytes due to the stagnation of bile acids and their detergent effects. Hydropic swelling of hepatocytes with a clearing of their cytoplasm is demonstrated, and the remaining cytoplasm concentration in the perinuclear region with the formation of Mallory bodies in addition to copper-binding protein accumulation, stained by orcein, in autophagic vacuoles.[8] Acute complete obstruction of the extrahepatic bile ducts is manifested as portal edema and centrilobular bilirubinostasis in the early stage, followed by cholangitis (ie, neutrophilic inflammation around the periportal ductules) and parenchymal bilirubinostasis which extends into the periportal areas. Chronic complete obstruction reveals all the classic features of cholestasis, which eventually leads to secondary biliary cirrhosis. On the other hand, chronic incomplete cholestasis reveals the periportal and parenchymal features of cholestasis, depending on the duration of obstruction. Bilirubinostasis, however, may remain absent for long periods in chronic incomplete obstruction.

Clinical History Identifying additional associated acute or chronic clinical features in patients with cholestatic jaundice is essential to diagnosing the underlying etiology. A rapid onset suggests acute pathology, while a gradual and insidious onset may indicate malignancy or other chronic causes. A thorough history is crucial for a patient with a new onset of jaundice. Historical features that may indicate a specific etiology include: Pain, especially in the epigastrium or right upper quadrant, before the onset of jaundice might suggest choledocholithiasis or cholecystitis, which causes Mirizzi syndrome. Fever is highly suggestive of cholangitis. The onset of jaundice after any hepatobiliary surgery may indicate bile duct injury or bile duct leak; however, jaundice is not always present in cholestasis. Any history of critical illness or shock may result in cholestasis of sepsis. Any recent medication use (eg, antibiotics) can cause cholestasis. The insidious onset of jaundice with nausea, vomiting, and prodrome phase is suggestive of viral hepatitis. A history of prior travel, sexual contact, blood transfusion, or intravenous drug use can support this diagnosis. A family history or personal history of any autoimmune disease can indicate PSC or PBC. Other clinical features observed in patients with chronic cholestasis include: Pruritus: Pruritus is commonly associated with chronic cholestasis, although it is often misdiagnosed as a primary dermatological condition, particularly in patients without jaundice. Patients typically report that the pruritus is better in the morning and worse at night; it may also occur intermittently throughout the disease process. This itching may be secondary to pruritogenic bile salts, which are elevated in cholestatic liver conditions that accumulate under the skin. Fatigue: Approximately 70% to 80% of patients with chronic cholestasis have fatigue that is thought to originate in the central nervous system and is related to underlying abnormal serotonergic neurotransmission or neuroendocrine defects in the corticotrophin hormone axis. However, the presence or severity of fatigue does not correlate to disease state or other disease-related biomarkers.

Fatigue: Approximately 70% to 80% of patients with chronic cholestasis have fatigue that is thought to originate in the central nervous system and is related to underlying abnormal serotonergic neurotransmission or neuroendocrine defects in the corticotrophin hormone axis. However, the presence or severity of fatigue does not correlate to disease state or other disease-related biomarkers. Fat-soluble vitamin deficiency symptoms: Bile is necessary to absorb ingested fat-soluble vitamins (A, D, E, and K). In chronic cholestasis, a deficiency of these vitamins may occur, leading to clinical features of their deficiency. Xanthomas: Flat or slightly raised yellow skin (lipid-laden) deposits are usually present around the eyes but can be present in palmar creases and other body parts. Physical Examination The extent of jaundice generally reflects the degree of hyperbilirubinemia. Icterus may be seen on examination in the conjunctiva, oral mucosa, and skin throughout the body. Cachexia or wasting noted on general examination may indicate cancer or cirrhosis. Findings of diffuse lymphadenopathy, especially Virchow’s node, can suggest underlying malignancy. Additionally, in chronic cholestasis, skin findings include excoriations due to pruritus, melanin pigmentation, xanthomas of the eyelids, extensor surfaces, and palmar creases. The presence of spider angiomas might suggest chronic liver disease or cirrhosis. Abdominal examination may demonstrate a large, nodular liver suggestive of hepatic metastasis. Tender hepatomegaly may be seen in viral hepatitis, congestive heart failure, and alcohol-related hepatitis. In choledocholithiasis and cholecystitis, tenderness in the right upper quadrant may be appreciated. Splenomegaly can be seen due to massive hemolysis or portal hypertension. Ascites can be observed in cirrhosis due to portal hypertension.

Diagnostic studies used to evaluate cholestatic jaundice involve a combination of clinical examination, liver function tests, imaging studies like ultrasound or magnetic resonance cholangiopancreatography (MRCP), and sometimes liver biopsy.[9][10][11][12] Liver Chemistry Panel Serum total and fractioned direct bilirubin should be obtained. A predominantly direct hyperbilirubinemia (more than 50% of total bilirubin) is observed in cholestasis. Serum alkaline phosphatase is often elevated 3 times greater than the upper standard limit of normal, while the hepatic transaminases may be normal or only mildly elevated. Serum albumin is usually normal except in cirrhosis and late chronic liver disease. Hematology Hematologic findings can assist in identifying the etiology of cholestatic jaundice, including: Leukocytosis: This finding may indicate cholangitis, alcohol-related hepatitis, and underlying malignancy. Acute severe anemia: Severe anemia may occur due to hemolysis. Evaluation of peripheral smear and reticulocyte count can help differentiate between these 2 entities. Chronic anemia can be seen in cirrhosis or underlying malignancy. Elevated prothrombin time: This finding can be seen with cholestasis, which rapidly reverses with vitamin K supplementation compared to patients with cirrhosis and hepatic synthetic dysfunction. Radiological Evaluation Abdominal ultrasound can help identify biliary ductal dilation and differentiate between hepatocellular causes of cholestasis (where the ducts are normal) and biliary obstruction (where the ducts are dilated). If dilated biliary ducts are encountered on initial ultrasound, MRCP can be used to assess the bile ducts further and identify stones, strictures, or features of malignancy. While a computed tomography scan can be helpful, MRCP has better sensitivity. Liver Biopsy A liver biopsy can be helpful in cases of suspected intrahepatic cholestasis when there is diagnostic uncertainty.

The management of cholestatic jaundice depends upon the underlying etiology. The mainstay of obstructive cholestasis is biliary decompression.[13][14][15][16][17] Management of hepatocellular cholestasis includes treatment of the underlying disease and associated symptoms. Biliary Decompression Endoscopic sphincterotomy, with or without stent placement, can relieve obstruction due to bile duct stones. Similarly, dilation and stent placement can alleviate the obstruction in benign common bile duct strictures. Surgical resection of the obstructive lesion is preferred in the case of malignant obstruction and depends upon the disease stage and the patient's operative candidacy. Hepaticojejunostomy with Roux-en-Y bypass is an option if complete resection is not possible. If the patient is not a surgical candidate, palliation can be achieved with an endoscopically placed common bile duct stent, usually a metal stent. If endoscopic stent placement is not successful, a percutaneous transhepatic cholangiography tube can be placed for biliary decompression. Antibiotics are considered in the prebiliary and postbiliary decompression phases to reduce the risk of sepsis. Management of  Pruritus In cases of obstructive physiology, pruritus may be relieved within 24 to 48 hours of biliary decompression. In other cases, medications may be needed for symptomatic control.[18] Medications options include: Ursodeoxycholic acid: This is recommended in doses of 13 to 15 mg/kg daily to treat the underlying condition in patients with cholestasis due to PBC and the pruritus associated with intrahepatic cholestasis of pregnancy. Antihistamines: These may be used for mild symptoms in patients with insomnia resulting from pruritus. They may benefit from the sedating effects. Cholestyramine: This bile acid sequestrant is considered first-line therapy for moderate to severe symptoms and is prescribed at a starting dose of 4 g to a maximum dose of 16 g, administered once or twice daily. Maximum dose is achieved by increasing the dose by 4 g daily every 4 weeks. Cholestyramine is best administered before breakfast to enhance the excretion of pruritogens, believed to have been stored in the gallbladder during the overnight fast. Patients should take the minimal effective dose to avoid adverse events, eg, nausea, steatorrhea, and fat-soluble vitamin malabsorption.

Cholestyramine: This bile acid sequestrant is considered first-line therapy for moderate to severe symptoms and is prescribed at a starting dose of 4 g to a maximum dose of 16 g, administered once or twice daily. Maximum dose is achieved by increasing the dose by 4 g daily every 4 weeks. Cholestyramine is best administered before breakfast to enhance the excretion of pruritogens, believed to have been stored in the gallbladder during the overnight fast. Patients should take the minimal effective dose to avoid adverse events, eg, nausea, steatorrhea, and fat-soluble vitamin malabsorption. Rifampin: This drug is used if cholestyramine does not relieve pruritus; this has been shown to improve pruritus when administered 150 mg to 300 mg twice daily. Serious adverse events include hepatitis, renal failure, and hemolytic anemia. Therefore, regular monitoring of aminotransferases is recommended. Naltrexone: This is an opioid antagonist administered at 12.5 mg to 50 mg daily. The efficacy is thought to be related to the role of endogenous opioids in the pathogenesis of cholestatic pruritus. This should not be prescribed to patients receiving opioid medications and should be used with caution in patients with underlying chronic pain conditions. Sertraline: This selective serotonin reuptake inhibitor has shown some efficacy in improving pruritus in small series when administered at 75 to 100 mg daily. Nonpharmacological treatment options include ultraviolet light and plasmapheresis. These modalities are generally less effective, expensive, and not readily available for routine care of patients with pruritus. Surgical resection of less than 15% of the terminal ileum to prevent enterohepatic circulation (bile salt reabsorption) can be effective in intractable pruritus. This intervention may be reserved for refractory cases. Liver transplantation may be the only effective therapy for intractable cases of pruritus, but this is not a standard indication.

Differential diagnoses that should be considered when evaluating cholestatic jaundice include: Acute liver failure Acute hepatitis Acute pancreatitis Amyloidosis Autoimmune hepatitis Biliary obstruction Cholangitis Cholecystitis Cirrhosis

Managing cholestatic jaundice demands a coordinated, interprofessional approach to optimize patient-centered care and safety. Clinicians are central to diagnosis and developing tailored care plans, leveraging clinical expertise and diagnostic tools to determine the underlying etiology. Gastroenterologists, surgeons, and radiologists provide specialized skills for interventions such as biliary decompression or imaging studies, which are essential in cases of obstructive cholestasis. Nurses play a critical role in patient monitoring, ensuring continuity of care, educating patients and families, and identifying early signs of complications. Pharmacists contribute by managing medication regimens to control symptoms like pruritus and preventing potential drug interactions or adverse events. Effective care coordination hinges on clear interprofessional communication to ensure seamless transitions across care settings. This includes regular team discussions, detailed handoffs, and shared decision-making involving the patient and their family. Advanced clinicians and nurses facilitate these interactions by liaising between patients and specialists, reinforcing adherence to care plans. Collectively, this collaborative strategy enhances team performance, improves patient outcomes, and minimizes risks. By fostering mutual accountability and prioritizing holistic care, the healthcare team can address the complexities of cholestatic jaundice and deliver high-quality care tailored to each patient’s needs.